Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Breast 1

Conditions

Prostatic Neoplasms 46Breast Neoplasms 9Salivary Gland Neoplasms 2Prostate Adenocarcinoma 2Neoplasm Metastasis 2Breast Neoplasms, Male 2Stage I Prostate Adenocarcinoma AJCC v7 1Sexual Dysfunctions, Psychological 1Salivary Gland Neoplasm Duct 1Primary Dysautonomias 1Patient Compliance 1PSA Level Greater Than Two 1Newly Diagnosed Oligometastatic Prostate Cancer 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia 1Kidney Diseases 1Hypertension 1Hormone Sensitive Prostate Cancer 1Hereditary Sensory and Autonomic Neuropathies 1HER2-positive Breast Cancer 1Granulosa cell tumor of the ovary 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

exemestane 1Leuprolide 1Letrozole 1Holistic Health 1Goserelin 1Gonadotropin-Releasing Hormone 1Bupropion 1Aromatase Inhibitors 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sexual Dysfunctions, Psychological × Leuprolide × 1 year × Clear all
NCT07596212 2026-05-19

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

University of Illinois at Chicago

Phase 1/2 Not yet recruiting
100 enrolled
BreastOther

Breast Neoplasms, Sexual Dysfunctions, Psychological

Data powered by HemOnc (CC BY 4.0) Colophon âš¡